Table 3.

Mean and estimated mean changes in clinical assessments from the baseline to 24-week follow-up and the baseline to 48-week follow-up.

		Baseline	24 weeks	48 weeks	Mean change ΔBaseline-24 weeks	P value	Mean change ΔBaseline-48 weeks	P value
MMSE score	M. officinalis (n = 10) Placebo group (n = 10)	23.40 ± 1.58 23.70 ± 1.83	22.10 ± 2.73 22.40 ± 3.47	21.30 ± 3.86 23.30 ± 3.78	− 1.30 ± 2.36  − 1.30 ± 2.36	0.513	− 2.10 ± 3.73  − 0.40 ± 2.27	0.459
ADAS-cog score	M. officinalis (n = 10) Placebo group (n = 10)	23.90 ± 4.79 24.30 ± 4.37	23.60 ± 4.84 26.10 ± 6.17	26.30 ± 3.13 25.90 ± 8.63	− 0.30 ± 4.35 1.80 ± 3.88	0.239	2.40 ± 5.50 1.60 ± 5.32	0.657
DAD score	M. officinalis (n = 10) Placebo group (n = 10)	30.10 ± 7.31 27.90 ± 5.53	30.30 ± 5.74 27.40 ± 5.91	28.60 ± 5.73 25.20 ± 8.47	0.20 ± 1.99  − 0.50 ± 3.03	0.464	− 1.50 ± 4.50  − 2.70 ± 3.77	0.828
NPI-Q score	M. officinalis (n = 10) Placebo group (n = 10)	4.60 ± 3.84 4.80 ± 1.81	4.10 ± 3.51 5.50 ± 2.17	3.50 ± 3.03 6.10 ± 2.08	− 0.50 ± 1.43 0.70 ± 1.89	0.012	− 1.10 ± 2.54 1.30 ± 2.54	< 0.001
CDR score	M. officinalis (n = 10) Placebo group (n = 10)	1.0 (n = 10) 1.0 (n = 10)	1.0 (n = 10) 1.0 (n = 9) 2.0 (n = 1)	1.0 (n = 10) 1.0 (n = 9) 2.0 (n = 1)	–	–	–	–

ADAS-cog cognitive subscale of the Alzheimer’s Disease Assessment Scale; CDR clinical dementia rating; DAD Disability Assessment for Dementia; M. officinalis, Melissa officinalis; MMSE Mini-Mental State Examination; NPI-Q Neuropsychiatric Inventory-Questionnaire.